Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers


  Inflammatory Bowel Diseases

  Free Subscription

Articles published in Gut

Retrieve available abstracts of 143 articles:
HTML format

Single Articles

    April 2020
  1. KENNEDY NA, Jones GR, Lamb CA, Appleby R, et al
    British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.
    Gut. 2020 Apr 17. pii: gutjnl-2020-321244. doi: 10.1136/gutjnl-2020-321244.
    PubMed     Abstract available

  2. MAZZA S, Sorce A, Peyvandi F, Vecchi M, et al
    A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis.
    Gut. 2020 Apr 3. pii: gutjnl-2020-321183. doi: 10.1136/gutjnl-2020-321183.

  3. FAIRBRASS KM, Hoshen D, Gracie DJ, Ford AC, et al
    Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease.
    Gut. 2020 Apr 2. pii: gutjnl-2020-321186. doi: 10.1136/gutjnl-2020-321186.

    March 2020
  4. VALLERAND I, Frolkis AD, Patten S, Kaplan GG, et al
    Changing trends in coding for depression among the UK IBD population: reply from authors.
    Gut. 2020;69:607.

  5. POWELL N, Pantazi E, Pavlidis P, Tsakmaki A, et al
    Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells.
    Gut. 2020;69:578-590.
    PubMed     Abstract available

  6. VAN DER GIESSEN J, Binyamin D, Belogolovski A, Frishman S, et al
    Modulation of cytokine patterns and microbiome during pregnancy in IBD.
    Gut. 2020;69:473-486.
    PubMed     Abstract available

  7. SOKOL H, Brot L, Stefanescu C, Auzolle C, et al
    Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease.
    Gut. 2020;69:462-472.
    PubMed     Abstract available

  8. OLEN O, Askling J, Sachs MC, Neovius M, et al
    Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014.
    Gut. 2020;69:453-461.
    PubMed     Abstract available

    February 2020
  9. MURTHY SK, Begum J, Benchimol EI, Bernstein CN, et al
    Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
    Gut. 2020;69:274-282.
    PubMed     Abstract available

  10. SUN R, Hedl M, Abraham C
    IL23 group> IL23R recycling and amplifies innate receptor-induced signalling and cytokines in human macrophages, and the IBD-protective IL23R R381Q variant modulates these outcomes.
    Gut. 2020;69:264-273.
    PubMed     Abstract available

  11. SCHLEIER L, Wiendl M, Heidbreder K, Binder MT, et al
    Non-classical monocyte homing to the gut via alpha4beta7 integrin mediates macrophage-dependent intestinal wound healing.
    Gut. 2020;69:252-263.
    PubMed     Abstract available

    January 2020
  12. DOLMAN GE, Kennedy PTF
    Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease.
    Gut. 2020 Jan 30. pii: gutjnl-2019-319480. doi: 10.1136/gutjnl-2019-319480.

  13. BOSSUYT P, Nakase H, Vermeire S, de Hertogh G, et al
    Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density.
    Gut. 2020 Jan 8. pii: gutjnl-2019-320056. doi: 10.1136/gutjnl-2019-320056.
    PubMed     Abstract available

  14. NG SC, Kamm MA, Yeoh YK, Chan PKS, et al
    Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE).
    Gut. 2020;69:83-91.
    PubMed     Abstract available

  15. TORRES J, Hu J, Seki A, Eisele C, et al
    Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice.
    Gut. 2020;69:42-51.
    PubMed     Abstract available

  16. TURNER D, Griffiths AM, Wilson D, Mould DR, et al
    Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary.
    Gut. 2020;69:32-41.
    PubMed     Abstract available

  17. WAN QY, Zhao R, Wu XT
    Older patients with IBD might have higher risk of Parkinson's disease.
    Gut. 2020;69:193-194.

  18. TULKENS J, Vergauwen G, Van Deun J, Geeurickx E, et al
    Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.
    Gut. 2020;69:191-193.

    December 2019
  19. MAASER C, Petersen F, Helwig U, Fischer I, et al
    Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study.
    Gut. 2019 Dec 20. pii: gutjnl-2019-319451. doi: 10.1136/gutjnl-2019-319451.
    PubMed     Abstract available

  20. CHA JM, Park SH, Rhee KH, Hong SN, et al
    Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea.
    Gut. 2019 Dec 10. pii: gutjnl-2019-319699. doi: 10.1136/gutjnl-2019-319699.
    PubMed     Abstract available

  21. DE BARRIOS O, Sanchez-Moral L, Cortes M, Ninfali C, et al
    ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells.
    Gut. 2019;68:2129-2141.
    PubMed     Abstract available

  22. LIMKETKAI BN, Shah SC, Hirano I, Bellaguarda E, et al
    Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis.
    Gut. 2019;68:2152-2160.
    PubMed     Abstract available

    November 2019
  23. JONES GR, Lyons M, Plevris N, Jenkinson PW, et al
    IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology.
    Gut. 2019;68:1953-1960.
    PubMed     Abstract available

  24. ALLEZ M, Auzolle C, Ngollo M, Bottois H, et al
    T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence.
    Gut. 2019;68:1961-1970.
    PubMed     Abstract available

  25. PAI RK, Khanna R, D'Haens GR, Sandborn WJ, et al
    Definitions of response and remission for the Robarts Histopathology Index.
    Gut. 2019;68:2101-2102.

    October 2019
  26. DE GROOF EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, et al
    Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.
    Gut. 2019;68:1774-1780.
    PubMed     Abstract available

    September 2019
  27. LAMB CA, Kennedy NA, Raine T, Hendy PA, et al
    British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
    Gut. 2019 Sep 27. pii: gutjnl-2019-318484. doi: 10.1136/gutjnl-2019-318484.
    PubMed     Abstract available

  28. VILLUMSEN M, Aznar S, Pakkenberg B, Brudek T, et al
    Authors' response: Association between IBD and Parkinson's disease: seek and you shall find?
    Gut. 2019;68:1722.

  29. PARKES M
    IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn's and Colitis.
    Gut. 2019;68:1537-1540.

    August 2019
  30. VERSTOCKT B, Verstockt S, Blevi H, Cleynen I, et al
    TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?
    Gut. 2019;68:1531-1533.

  31. BIASCI D, Lee JC, Noor NM, Pombal DR, et al
    A blood-based prognostic biomarker in IBD.
    Gut. 2019;68:1386-1395.
    PubMed     Abstract available

    July 2019
  32. WALDSCHMITT N, Kitamoto S, Secher T, Zacharioudaki V, et al
    The regenerating family member 3 beta instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signalling for controlling colonisation resistance independently of microbiota community structure.
    Gut. 2019;68:1190-1199.
    PubMed     Abstract available

  33. TITO RY, Chaffron S, Caenepeel C, Lima-Mendez G, et al
    Population-level analysis of Blastocystis subtype prevalence and variation in the human gut microbiota.
    Gut. 2019;68:1180-1189.
    PubMed     Abstract available

    June 2019
  34. PETERSEN BS, Bokemeyer B, Wenker C, Hoby S, et al
    First known case of paediatric inflammatory bowel disease in a western lowland gorilla may be linked to a familial mutation in the MEFV gene.
    Gut. 2019 Jun 21. pii: gutjnl-2019-319051. doi: 10.1136/gutjnl-2019-319051.

  35. DANESE S, Argollo M, Le Berre C, Peyrin-Biroulet L, et al
    JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
    Gut. 2019 Jun 21. pii: gutjnl-2019-318448. doi: 10.1136/gutjnl-2019-318448.
    PubMed     Abstract available

  36. BETTENWORTH D, Bokemeyer A, Baker M, Mao R, et al
    Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review.
    Gut. 2019;68:1115-1126.
    PubMed     Abstract available

    May 2019
  37. ZUNDLER S, Becker E, Schulze LL, Neurath MF, et al
    Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Gut. 2019 May 24. pii: gutjnl-2018-317977. doi: 10.1136/gutjnl-2018-317977.
    PubMed     Abstract available

  38. LYNGE E, Petersen MS, Lophaven SN
    Inflammatory bowel disease and Parkinson's disease.
    Gut. 2019 May 10. pii: gutjnl-2019-318958. doi: 10.1136/gutjnl-2019-318958.

  39. BUTWICKA A, Sariaslan A, Larsson H, Halfvarson J, et al
    No association between urbanisation, neighbourhood deprivation and IBD: a population-based study of 4 million individuals.
    Gut. 2019;68:947-948.

  40. MEDDENS CA, van der List ACJ, Nieuwenhuis EES, Mokry M, et al
    Non-coding DNA in IBD: from sequence variation in DNA regulatory elements to novel therapeutic potential.
    Gut. 2019;68:928-941.
    PubMed     Abstract available

  41. SCHMITT H, Billmeier U, Dieterich W, Rath T, et al
    Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
    Gut. 2019;68:814-828.
    PubMed     Abstract available

    April 2019
  42. LEMOINNE S, Kemgang A, Ben Belkacem K, Straube M, et al
    Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis.
    Gut. 2019 Apr 19. pii: gutjnl-2018-317791. doi: 10.1136/gutjnl-2018-317791.
    PubMed     Abstract available

  43. GAUJOUX R, Starosvetsky E, Maimon N, Vallania F, et al
    Cell-centred meta-analysis reveals baseline predictors of anti-TNFalpha non-response in biopsy and blood of patients with IBD.
    Gut. 2019;68:604-614.
    PubMed     Abstract available

  44. TOMINAGA K, Tsuchiya A, Yokoyama J, Terai S, et al
    How do you treat this diversion ileitis and pouchitis?
    Gut. 2019;68:593-758.

  45. MAGRO F, Lopes J, Borralho P, Lopes S, et al
    Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels.
    Gut. 2019;68:594-603.
    PubMed     Abstract available

    March 2019
  46. VAN DER POST S, Jabbar KS, Birchenough G, Arike L, et al
    Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis.
    Gut. 2019 Mar 26. pii: gutjnl-2018-317571. doi: 10.1136/gutjnl-2018-317571.
    PubMed     Abstract available

  47. FROLKIS AD, Vallerand IA, Patten SB, Kaplan GG, et al
    Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors.
    Gut. 2019 Mar 20. pii: gutjnl-2019-318650. doi: 10.1136/gutjnl-2019-318650.

  48. ZUO T, Lu XJ, Zhang Y, Cheung CP, et al
    Gut mucosal virome alterations in ulcerative colitis.
    Gut. 2019 Mar 6. pii: gutjnl-2018-318131. doi: 10.1136/gutjnl-2018-318131.
    PubMed     Abstract available

    February 2019
  49. MOULTON CD, Norton C, Powell N, Mohamedali Z, et al
    Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation?
    Gut. 2019 Feb 26. pii: gutjnl-2019-318444. doi: 10.1136/gutjnl-2019-318444.

  50. BLACKWELL J, Saxena S, Pollok RC
    Changing trends in coding for depression among the UK inflammatory bowel disease population.
    Gut. 2019 Feb 13. pii: gutjnl-2019-318296. doi: 10.1136/gutjnl-2019-318296.

  51. HARPAZ N, Ballentine S, Colombel JF, E Sands B, et al
    Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity.
    Gut. 2019 Feb 5. pii: gutjnl-2018-318137. doi: 10.1136/gutjnl-2018-318137.

  52. SAHNAN K, Tozer PJ, Adegbola SO, Lee MJ, et al
    Developing a core outcome set for fistulising perianal Crohn's disease.
    Gut. 2019;68:226-238.
    PubMed     Abstract available

  53. LEVINE A, Kori M, Kierkus J, Sigall Boneh R, et al
    Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial.
    Gut. 2019;68:239-247.
    PubMed     Abstract available

    January 2019
  54. VIGOD SN, Kurdyak P, Brown HK, Nguyen GC, et al
    Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study.
    Gut. 2019 Jan 9. pii: gutjnl-2018-317610. doi: 10.1136/gutjnl-2018-317610.
    PubMed     Abstract available

  55. ROGLER G
    Mechanism of action of vedolizumab: do we really understand it?
    Gut. 2019;68:4-5.

  56. HUTFLESS S, Wenning GK
    Which way does the axis tip? IBD increases the risk of Parkinson's disease.
    Gut. 2019;68:3.

  57. GOUYNOU C, Pouillon L, Rousseau H, Zallot C, et al
    Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation.
    Gut. 2019;68:178-179.

  58. DANESE S, Vermeire S, Hellstern P, Panaccione R, et al
    Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).
    Gut. 2019;68:40-48.
    PubMed     Abstract available

    December 2018
  59. IACUCCI M, Furfaro F, Matsumoto T, Uraoka T, et al
    Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era.
    Gut. 2018 Dec 22. pii: gutjnl-2017-315235. doi: 10.1136/gutjnl-2017-315235.
    PubMed     Abstract available

  60. STJARNGRIM J, Ekbom A, Hammar U, Hultcrantz R, et al
    Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population?
    Gut. 2018 Dec 15. pii: gutjnl-2018-316651. doi: 10.1136/gutjnl-2018-316651.
    PubMed     Abstract available

  61. BLACKWELL J, Saxena S, Pollok RC
    Role of thiopurines as disease-modifying agents in Crohn's disease.
    Gut. 2018;67:2229-2230.

    November 2018
  62. UNGARO RC, Limketkai BN, Jensen CB, Allin KH, et al
    Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.
    Gut. 2018 Nov 12. pii: gutjnl-2018-317021. doi: 10.1136/gutjnl-2018-317021.
    PubMed     Abstract available

    October 2018
  63. FROLKIS AD, Vallerand IA, Shaheen AA, Lowerison MW, et al
    Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression.
    Gut. 2018 Oct 18. pii: gutjnl-2018-317182. doi: 10.1136/gutjnl-2018-317182.
    PubMed     Abstract available

  64. HAMMOUDI N, Gardair C, Tran-Minh ML, Allez M, et al
    Rare cause of rectal stenosis in a patient with long-term use of Infliximab and Mercaptopurine for ulcerative colitis.
    Gut. 2018 Oct 9. pii: gutjnl-2018-317069. doi: 10.1136/gutjnl-2018-317069.
    PubMed     Abstract available

  65. XU P, Becker H, Elizalde M, Masclee A, et al
    Intestinal organoid culture model is a valuable system to study epithelial barrier function in IBD.
    Gut. 2018;67:1905-1906.

  66. SANDBORN WJ, Lee SD, Tarabar D, Louis E, et al
    Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
    Gut. 2018;67:1824-1835.
    PubMed     Abstract available

  67. GERNER RR, Klepsch V, Macheiner S, Arnhard K, et al
    NAD metabolism fuels human and mouse intestinal inflammation.
    Gut. 2018;67:1813-1823.
    PubMed     Abstract available

    September 2018
  68. VAZQUEZ-BAEZA Y, Gonzalez A, Xu ZZ, Washburne A, et al
    Guiding longitudinal sampling in IBD cohorts.
    Gut. 2018;67:1743-1745.

  69. LEVINE A, Sigall Boneh R, Wine E
    Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases.
    Gut. 2018;67:1726-1738.
    PubMed     Abstract available

    August 2018
  70. TAN LZ, Reilly CR, Steward-Harrison LC, Balouch F, et al
    Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis.
    Gut. 2018 Aug 21. pii: gutjnl-2018-316599. doi: 10.1136/gutjnl-2018-316599.

  71. JAIRATH V, Peyrin-Biroulet L, Zou G, Mosli M, et al
    Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.
    Gut. 2018 Aug 3. pii: gutjnl-2018-316702. doi: 10.1136/gutjnl-2018-316702.
    PubMed     Abstract available

  72. CONCEICAO-NETO N, Deboutte W, Dierckx T, Machiels K, et al
    Low eukaryotic viral richness is associated with faecal microbiota transplantation success in patients with UC.
    Gut. 2018;67:1558-1559.

    July 2018
  73. POTTER MDE, Walker MM, Keely S, Talley NJ, et al
    What's in a name? 'Non-coeliac gluten or wheat sensitivity': controversies and mechanisms related to wheat and gluten causing gastrointestinal symptoms or disease.
    Gut. 2018 Jul 30. pii: gutjnl-2018-316360. doi: 10.1136/gutjnl-2018-316360.

  74. MAO R, Chen Y, Xie X, Chen M, et al
    Gastrointestinal ultrasound in inflammatory bowel disease: experience from the Chinese IBD Elite Union.
    Gut. 2018 Jul 27. pii: gutjnl-2018-317070. doi: 10.1136/gutjnl-2018-317070.

  75. WEIMERS P, Halfvarson J, Sachs MC, Ludvigsson JF, et al
    Association between inflammatory bowel disease and Parkinson's disease: seek and you shall find?
    Gut. 2018 Jul 18. pii: gutjnl-2018-316937. doi: 10.1136/gutjnl-2018-316937.

  76. BAKER AM, Cross W, Curtius K, Al Bakir I, et al
    Evolutionary history of human colitis-associated colorectal cancer.
    Gut. 2018 Jul 10. pii: gutjnl-2018-316191. doi: 10.1136/gutjnl-2018-316191.
    PubMed     Abstract available

  77. KIRCHGESNER J, Beaugerie L, Carrat F, Andersen NN, et al
    Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study.
    Gut. 2018;67:1261-1268.
    PubMed     Abstract available

    June 2018
  78. KOTZE PG, Shen B, Lightner A, Yamamoto T, et al
    Modern management of perianal fistulas in Crohn's disease: future directions.
    Gut. 2018;67:1181-1194.
    PubMed     Abstract available

  79. BISSCHOPS R, Bessissow T, Joseph JA, Baert F, et al
    Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial.
    Gut. 2018;67:1087-1094.
    PubMed     Abstract available

  80. ZHOU G, Yu L, Fang L, Yang W, et al
    CD177(+) neutrophils as functionally activated neutrophils negatively regulate IBD.
    Gut. 2018;67:1052-1063.
    PubMed     Abstract available

    May 2018
  81. VILLUMSEN M, Aznar S, Pakkenberg B, Jess T, et al
    Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014.
    Gut. 2018 May 21. pii: gutjnl-2017-315666. doi: 10.1136/gutjnl-2017-315666.
    PubMed     Abstract available

  82. ZEISSIG S, Rosati E, Dowds CM, Aden K, et al
    Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Gut. 2018 May 5. pii: gutjnl-2018-316023. doi: 10.1136/gutjnl-2018-316023.
    PubMed     Abstract available

  83. TEN HOVE JR, Shah SC, Shaffer SR, Bernstein CN, et al
    Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study.
    Gut. 2018 May 2. pii: gutjnl-2017-315440. doi: 10.1136/gutjnl-2017-315440.
    PubMed     Abstract available

  84. VAN STAPPEN T, Vande Casteele N, Van Assche G, Ferrante M, et al
    Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.
    Gut. 2018;67:818-826.
    PubMed     Abstract available

    April 2018
  85. ERIKSSON C, Rundquist S, Cao Y, Montgomery S, et al
    Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study.
    Gut. 2018 Apr 4. pii: gutjnl-2017-315521. doi: 10.1136/gutjnl-2017-315521.
    PubMed     Abstract available

  86. MOUSSATA D, Allez M, Cazals-Hatem D, Treton X, et al
    Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?
    Gut. 2018;67:616-624.
    PubMed     Abstract available

    March 2018
  87. OKUGAWA Y, Toiyama Y, Kusunoki M, Goel A, et al
    Re: Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study.
    Gut. 2018 Mar 13. pii: gutjnl-2018-316205. doi: 10.1136/gutjnl-2018-316205.

    February 2018
  88. BRYANT RV, Friedman A, Wright EK, Taylor K, et al
    Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application.
    Gut. 2018 Feb 3. pii: gutjnl-2017-315655. doi: 10.1136/gutjnl-2017-315655.
    PubMed     Abstract available

  89. LAHARIE D, Bourreille A, Branche J, Allez M, et al
    Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.
    Gut. 2018;67:237-243.
    PubMed     Abstract available

  90. SIEGEL CA, Whitman CB, Spiegel BMR, Feagan B, et al
    Development of an index to define overall disease severity in IBD.
    Gut. 2018;67:244-254.
    PubMed     Abstract available

    January 2018
  91. ORTQVIST AK, Lundholm C, Halfvarson J, Ludvigsson JF, et al
    Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study.
    Gut. 2018 Jan 10. pii: gutjnl-2017-314352. doi: 10.1136/gutjnl-2017-314352.
    PubMed     Abstract available

  92. BOUHNIK Y, Carbonnel F, Laharie D, Stefanescu C, et al
    Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
    Gut. 2018;67:53-60.
    PubMed     Abstract available

  93. ARIJS I, De Hertogh G, Lemmens B, Van Lommel L, et al
    Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
    Gut. 2018;67:43-52.
    PubMed     Abstract available

  94. WEISER M, Simon JM, Kochar B, Tovar A, et al
    Molecular classification of Crohn's disease reveals two clinically relevant subtypes.
    Gut. 2018;67:36-42.
    PubMed     Abstract available

  95. CARBALLAL S, Maisterra S, Lopez-Serrano A, Gimeno-Garcia AZ, et al
    Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD.
    Gut. 2018;67:70-78.
    PubMed     Abstract available

  96. BOUHNIK Y, Mary JY
    Adalimumab in Crohn's disease and symptomatic small bowel strictures.
    Gut. 2018;67:199.

  97. SONAMBEKAR AA, Desai DC, Joshi A, Dhoble P, et al
    Adalimumab in Crohn's strictures--the CREOLE study.
    Gut. 2018;67:198.

    December 2017
  98. DANESE S, Fiorino G, Peyrin-Biroulet L
    Early intervention in Crohn's disease: towards disease modification trials.
    Gut. 2017;66:2179-2187.
    PubMed     Abstract available

  99. COLOMBEL JF, Keir ME, Scherl A, Zhao R, et al
    Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC.
    Gut. 2017;66:2063-2068.
    PubMed     Abstract available

    November 2017
  100. CHOI CR, Al Bakir I, Ding NJ, Lee GH, et al
    Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study.
    Gut. 2017 Nov 17. pii: gutjnl-2017-314190. doi: 10.1136/gutjnl-2017-314190.
    PubMed     Abstract available

  101. PALMELA C, Chevarin C, Xu Z, Torres J, et al
    Adherent-invasive Escherichia coli in inflammatory bowel disease.
    Gut. 2017 Nov 15. pii: gutjnl-2017-314903. doi: 10.1136/gutjnl-2017-314903.
    PubMed     Abstract available

  102. KIM HS, Cheon JH, Jung ES, Park J, et al
    A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD.
    Gut. 2017;66:1926-1935.
    PubMed     Abstract available

  103. ZUNDLER S, Schillinger D, Fischer A, Atreya R, et al
    Blockade of alphaEbeta7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo.
    Gut. 2017;66:1936-1948.
    PubMed     Abstract available

  104. ALLEZ M, Skolnick BE, Wisniewska-Jarosinska M, Petryka R, et al
    Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial.
    Gut. 2017;66:1918-1925.
    PubMed     Abstract available

  105. HOCHART A, Gower-Rousseau C, Sarter H, Fumery M, et al
    Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study.
    Gut. 2017;66:1912-1917.
    PubMed     Abstract available

  106. HOVING JC, Cutler AJ, Leeto M, Horsnell WGC, et al
    Interleukin 13-mediated colitis in the absence of IL-4Ralpha signalling.
    Gut. 2017;66:2037-2039.

    October 2017
  107. NORGARD BM, Magnussen B, Larsen MD, Friedman S, et al
    Reassuring results on birth outcomes in children fathered by men treated with azathioprine/6-mercaptopurine within 3 months before conception: a nationwide cohort study.
    Gut. 2017;66:1761-1766.
    PubMed     Abstract available

  108. JULSGAARD M, Kjeldsen J, Baumgart DC
    Vedolizumab safety in pregnancy and newborn outcomes.
    Gut. 2017;66:1866-1867.

  109. SOMMER F, Ruhlemann MC, Bang C, Hoppner M, et al
    Microbiomarkers in inflammatory bowel diseases: caveats come with caviar.
    Gut. 2017;66:1734-1738.

    September 2017
  110. BERTIN S, Aoki-Nonaka Y, Lee J, de Jong PR, et al
    The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1.
    Gut. 2017;66:1584-1596.
    PubMed     Abstract available

    When radiology meets gastroenterology: an unusual impact.
    Gut. 2017;66:1676.

    August 2017
  112. PARIAN A, Limketkai B, Koh J, Brant SR, et al
    Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis.
    Gut. 2017;66:1390-1397.
    PubMed     Abstract available

  113. NYBOE ANDERSEN N, Gortz S, Frisch M, Jess T, et al
    Reduced risk of UC in families affected by appendicitis: a Danish national cohort study.
    Gut. 2017;66:1398-1402.
    PubMed     Abstract available

  114. O'BRIEN CL, Bringer MA, Holt KE, Gordon DM, et al
    Comparative genomics of Crohn's disease-associated adherent-invasive Escherichia coli.
    Gut. 2017;66:1382-1389.
    PubMed     Abstract available

    July 2017
  115. SPILLER RC, Sloan TJ
    Do diverticula provide a unique niche for microbiota which can lead to activation of the innate immune system?
    Gut. 2017;66:1175-1176.

    June 2017
  116. PANES J, Sandborn WJ, Schreiber S, Sands BE, et al
    Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
    Gut. 2017;66:1049-1059.
    PubMed     Abstract available

  117. SCHWERD T, Pandey S, Yang HT, Bagola K, et al
    Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease.
    Gut. 2017;66:1060-1073.
    PubMed     Abstract available

  118. SOKOL H, Leducq V, Aschard H, Pham HP, et al
    Fungal microbiota dysbiosis in IBD.
    Gut. 2017;66:1039-1048.
    PubMed     Abstract available

    May 2017
  119. PARANG B, Kaz AM, Barrett CW, Short SP, et al
    BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis.
    Gut. 2017;66:852-862.
    PubMed     Abstract available

  120. PASCAL V, Pozuelo M, Borruel N, Casellas F, et al
    A microbial signature for Crohn's disease.
    Gut. 2017;66:813-822.
    PubMed     Abstract available

  121. LEE T, Clavel T, Smirnov K, Schmidt A, et al
    Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD.
    Gut. 2017;66:863-871.
    PubMed     Abstract available

  122. SCHEIBE K, Backert I, Wirtz S, Hueber A, et al
    IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo.
    Gut. 2017;66:823-838.
    PubMed     Abstract available

    April 2017
  123. LORD AR, Simms LA, Hanigan K, Sullivan R, et al
    Protective effects of Helicobacter pylori for IBD are related to the cagA-positive strain.
    Gut. 2017 Apr 13. pii: gutjnl-2017-313805. doi: 10.1136/gutjnl-2017-313805.

  124. LIN W, Ma C, Su F, Jiang Y, et al
    Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice.
    Gut. 2017;66:597-610.
    PubMed     Abstract available

    March 2017
  125. FRIEDMAN S, Larsen PV, Fedder J, Norgard BM, et al
    The reduced chance of a live birth in women with IBD receiving assisted reproduction is due to a failure to achieve a clinical pregnancy.
    Gut. 2017;66:556-558.

    February 2017
  126. NOBEN M, Verstockt B, de Bruyn M, Hendriks N, et al
    Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?
    Gut. 2017 Feb 3. pii: gutjnl-2016-313667. doi: 10.1136/gutjnl-2016-313667.

  127. SUBRAMANIAN S, Ekbom A, Rhodes JM
    Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?
    Gut. 2017;66:362-381.
    PubMed     Abstract available

  128. CASTANO-RODRIGUEZ N, Kaakoush NO, Lee WS, Mitchell HM, et al
    Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis.
    Gut. 2017;66:235-249.
    PubMed     Abstract available

  129. QURAISHI MN, Sergeant M, Kay G, Iqbal T, et al
    The gut-adherent microbiota of PSC-IBD is distinct to that of IBD.
    Gut. 2017;66:386-388.

    January 2017
  130. MOSLI MH, Feagan BG, Zou G, Sandborn WJ, et al
    Development and validation of a histological index for UC.
    Gut. 2017;66:50-58.
    PubMed     Abstract available

  131. MARCHAL-BRESSENOT A, Salleron J, Boulagnon-Rombi C, Bastien C, et al
    Development and validation of the Nancy histological index for UC.
    Gut. 2017;66:43-49.
    PubMed     Abstract available

  132. MACHIELS K, Sabino J, Vandermosten L, Joossens M, et al
    Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC.
    Gut. 2017;66:79-88.
    PubMed     Abstract available

  133. ATREYA I, Neurath MF
    Microbiota: relevant player in thiopurine metabolisation?
    Gut. 2017;66:1-3.

  134. DONG R, Zheng S, Chen G
    The appropriate dose and cost of iron replacement therapy in patients with IBD.
    Gut. 2017;66:196-197.

  135. GUINET-CHARPENTIER C, Lepage P, Morali A, Chamaillard M, et al
    Effects of enteral polymeric diet on gut microbiota in children with Crohn's disease.
    Gut. 2017;66:194-195.

    November 2016
  136. OLIVERA P, Danese S, Peyrin-Biroulet L
    Next generation of small molecules in inflammatory bowel disease.
    Gut. 2016 Nov 17. pii: gutjnl-2016-312912. doi: 10.1136/gutjnl-2016-312912.

  137. TEICH N, Bokemeyer B, Mohl W, Walldorf J, et al
    Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD.
    Gut. 2016 Nov 14. pii: gutjnl-2016-313138. doi: 10.1136/gutjnl-2016-313138.

  138. DOTTI I, Mora-Buch R, Ferrer-Picon E, Planell N, et al
    Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis.
    Gut. 2016 Nov 1. pii: gutjnl-2016-312609. doi: 10.1136/gutjnl-2016-312609.
    PubMed     Abstract available

    October 2016
  139. IMHANN F, Vich Vila A, Bonder MJ, Fu J, et al
    Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.
    Gut. 2016 Oct 8. pii: gutjnl-2016-312135. doi: 10.1136/gutjnl-2016-312135.
    PubMed     Abstract available

    September 2016
  140. HASLER R, Sheibani-Tezerji R, Sinha A, Barann M, et al
    Uncoupling of mucosal gene regulation, mRNA splicing and adherent microbiota signatures in inflammatory bowel disease.
    Gut. 2016 Sep 30. pii: gutjnl-2016-311651. doi: 10.1136/gutjnl-2016-311651.
    PubMed     Abstract available

    July 2016
  141. JENDREK ST, Gotthardt D, Nitzsche T, Widmann L, et al
    Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Gut. 2016 Jul 12. pii: gutjnl-2016-311739. doi: 10.1136/gutjnl-2016-311739.
    PubMed     Abstract available

    May 2016
  142. SABINO J, Vieira-Silva S, Machiels K, Joossens M, et al
    Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.
    Gut. 2016 May 20. pii: gutjnl-2015-311004. doi: 10.1136/gutjnl-2015-311004.
    PubMed     Abstract available

    June 2015
  143. HART PA, Levy MJ, Smyrk TC, Takahashi N, et al
    Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience.
    Gut. 2015 Jun 17. pii: gutjnl-2015-309275. doi: 10.1136/gutjnl-2015-309275.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.